Surprise drugs boost for Johnson & Johnson

Three months ago, Johnson & Johnson (J&J) predicted an ugly 2019 as the healthcare giant faced thousands of consumer lawsuits and pressure in the US on drug prices. But its latest quarterly results suggested the company may have been too pessimistic.

While sales are still being hurt by difficult foreign exchange rates, J&J’s fast-growing pharmaceutical unit helped offset its weaker consumer and medical device lines.